213250-64-7

Usage

Uses

Used in Pharmaceutical Industry:
[2-[(3'R,5'R)-3',5'-bis[(tert-butyldimethylsilyl)oxy]-4'-methylenecyclohexylidene]ethyl]diphenylphosphine oxide is used as an intermediate in the synthesis of vitamin D3 analogs. These analogs are essential for various biological functions, including regulation of calcium and phosphorus metabolism, bone health, and immune system modulation. The compound plays a crucial role in the development of pharmaceuticals targeting these applications.
Used in Chemical Synthesis:
In the chemical synthesis industry, [2-[(3'R,5'R)-3',5'-bis[(tert-butyldimethylsilyl)oxy]-4'-methylenecyclohexylidene]ethyl]diphenylphosphine oxide can be utilized as a building block or reagent for the creation of more complex molecules. Its unique structure and functional groups make it a valuable component in the synthesis of various organic compounds, potentially leading to new materials and applications in different fields.

Upstream product

• 213250-59-0 methyl (3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-methylenecyclohexanecarboxylate 
• 829-85-6 diphenylphosphane 
• 213250-63-6 2-((3R,5R)-3,5-bis(tertbutyldimethylsilyloxy)-4-methylenecyclohexylidene)ethanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 766529-88-8 (1R,3R,5R)-1-acetoxy-3-[(tert-butyldimethylsilyl)oxy]-6-oxa-bicyclo[3.2.1]octane-4,7-dione 
• 766529-94-6 (1R,3R,5R)-3-[(tert-butyldimethylsilyl)oxy]-1-hydroxy-6-oxa-bicyclo[3.2.1]octane-4,7-dione 
• 163217-18-3 (1R,3R,4S,5R)-3-[(tert-butyldimethylsilyl)oxy]-1,4-dihydroxy-6-oxa-bicyclo[3.2.1]octan-7-one 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 77-95-2 D-(-)-quinic acid 
• 213250-60-3 [(3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-methylenecyclohexyl]methanol 
• 213250-58-9 (3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-oxocyclohexanecarboxylic acid methyl ester 
• 213250-61-4 (3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-4-methylenecyclohexanone 
• 135711-62-5 methyl quinicate 
• 213250-62-5 methyl-2-((3R,5R)-3,5-bis(tertbutyldimethylsilyloxy)-4-methylenecyclohexylidene)acetate 

Downstream Products

• 213250-65-8 (1R,3R,7E,17β)-1,3-bis{[tert-butyl(dimethyl)silyl]oxy}-2-methylidene-17-{6-methyl-6-[(triethylsilyl)oxy]heptan-2-yl}-9,10-secoestra-5,7-diene 
• 364059-43-8 (1R,3aS,7aR)-4-[2-[(3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-4-methylene-cyclohexylidene]-eth-(E)-ylidene]-1-((S)-5-ethyl-1-methyl-5-triethylsilanyloxy-heptyl)-7a-methyl-octahydro-indene 
• 364059-48-3 (1R,3aS,7aR)-4-[2-[(3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-4-methylene-cyclohexylidene]-eth-(E)-ylidene]-7a-methyl-1-[(S)-1-methyl-4-(1-triethylsilanyloxy-cyclopentyl)-butyl]-octahydro-indene 
• 213250-69-2 (1R,3aS,7aR)-4-[2-[(3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-4-methylene-cyclohexylidene]-eth-(E)-ylidene]-1-((S)-1,5-dimethyl-5-triethylsilanyloxy-hexyl)-7a-methyl-octahydro-indene 
• 862590-22-5 C₅₀H₉₀O₅Si₃ 
• 905932-26-5 C₄₃H₈₀O₃Si₃ 
• 1154606-53-7 (2S)-2-((1R,3R,7E,17β)-1,3-bis{[tert-butyl(dimethyl)silyl]oxy}-2-methylene-9,10-secoestra-5,7-dien-17-yl)propyl pivalate 
• 1154606-65-1 C₄₀H₇₄O₂Si₂ 
• 1166898-21-0 (20S,25R)-1α-[(tert-butyldimethylsilyl)oxy]-2-methylene-25-[(tert-butyldimethylsilyl)oxy]-19,26-dinorvitamin D3 tert-butyldimethylsilyl ether 
• 1166870-26-3 (20S,25S)-1α-[(tert-butyldimethylsilyl)oxy]-2-methylene-25-[(tert-butyldimethylsilyl)oxy]-19,26-dinorvitamin D3 tert-butyldimethylsilyl ether 
• 1165745-30-1 1α-[(tert-butyldimethylsilyl)oxy]-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D3 tert-butyldimethylsilyl ether 
• 951407-26-4 C₄₃H₈₂O₃Si₃ 
• 1252046-94-8 ((1R,3R)-5-((E)-2-(1-(1-((S)-3-(tertbutyldimethylsilyloxy)-2,3-dimethylbutoxy)ethyl)-7α-methyldihydro-1H-inden-4(2H,5H,6H,7H,7αH)-ylidene)ethylidene)-2-methylenecyclohexane-1,3-diyl)bis(oxy)bis(tertbutyldimethylsilane) 

Relevant academic research and scientific papers

Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects

We have synthesized a novel vitamin D receptor agonist VS-105 ((1R,3R)-5-((E)-2-((3αS,7αS)-1-((R)-1-((S)-3-hydroxy-2, 3-dimethylbutoxy)ethyl)-7α-methyldihydro-1H-inden-4(2H,5H,6H,7H,7αH) -ylidene)ethylidene)-2-methylenecyclohexane-1,3-diol). Preparation o

VITAMIN D RECEPTOR AGONISTS AND USES THEREOF

Disclosed is a compound of Formula (I), in which R1, R2, R3, R4, R5, R6, X, and a are defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are a pharmaceutical composition comprising a compound or salt therof of Formula (I) and a method of treating a disease which benefits from the modulation of the vitamin D receptor, such as a bone disorder, cardiovascular disease, a cardiovascular complication associated with renal disease, endothelial dysfunction, hyperparathyroidism, hypocalcemia, an immune disorder, left ventricular hypertrophy, a proliferative disease, proteinuria, renal disease, and thrombosis.

2-ALKYLIDENE-19-NOR-VITAMIN D DERIVATIVES FOR THE TREATMENT OF OSTEOGENESIS IMPERFECTA

The present invention relates to the treatment of ostogenesis imperfecta by adminstering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative, optionally with a bisphosphonate. Particularly, the present invention relates to the treatmen

Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen

The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and an estrogen, or a pharmaceutically acceptable salt

Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bone morphogenetic protein

The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivatives and a bone morphogenetic protein or active fragment or

Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and parathyroid hormone

The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and parathyroid hormone or an active fragment or varian

Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate

The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and a bisphosphonate. Particularly, the present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-1α, 25-dihydroxyvitamin D3and a bisphosphonate.

Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a cyclooxgenase-2 inhibitor

The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and a cyclooxgenase-2 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof. Particularly, the present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-10,25-dihydroxyvitamin D3 and a cyclooxgenase-2 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof.

Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist

The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and an EP2 or EP4 selective agonist or a pharmaceutically acceptable salt or prodrug thereof. Particularly, the present invention relates to pharmaceutical compositions and methods comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 and an EP2 or EP4 selective agonist or a pharmaceutically acceptable salt or prodrug thereof.

Pharmaceutical composition and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist

The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and an estrogen agonistlantagonist or a pharmaceuticall